{"id":937065,"date":"2026-02-13T17:03:22","date_gmt":"2026-02-13T22:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/"},"modified":"2026-02-13T17:03:22","modified_gmt":"2026-02-13T22:03:22","slug":"ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/","title":{"rendered":"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Detailed SOL-1 data to be presented at the 49<\/em><br \/>\n        <sup><br \/>\n          <em>th<\/em><br \/>\n        <\/sup><br \/>\n        <em> Macula Society Annual Meeting <\/em>\n      <\/p>\n<p>BEDFORD, Mass., Feb.  13, 2026  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI\u2122 (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49<sup>th<\/sup> Macula Society Annual Meeting between February 25 \u2013 28, 2026.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tejwVvyqQcaRgw3k-JvCXb5Ur9tHrA_iAR-lVRHIXW3qA3Gn6Ixqa-o_y7nLE3710RoT_nI83GJ85JlvYC5YOq1M3athgAAkcqlb8evz6vM=\" rel=\"nofollow\" target=\"_blank\">Click here<\/a>\u00a0to register for the virtual webcast, which will begin at 8:00 AM ET.<\/p>\n<p>The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.<\/p>\n<p>Follow the Company on its website, LinkedIn, or X.<\/p>\n<p>DEXTENZA<sup>\u00ae<\/sup> is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8Yy7VoFaGkKReHdOk_bik_JHsDIlbhQvHSDTKtXV8uHYNqRA22HeVB9B69IBAnJK4ErIxNhAqKZW_Ww2NNOP6pgxHBiG8-7kFDrmPUOhSig=\" rel=\"nofollow\" target=\"_blank\">bslattery@ocutx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGRhMTEwNjAtMmFiOC00MTdhLWI3NmMtNjc1YzZiODlhNDQxLTEwMjI2MjktMjAyNi0wMi0xMy1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI\u2122 (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 \u2013 28, 2026. Click here\u00a0to register for the virtual webcast, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937065","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI\u2122 (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 \u2013 28, 2026. Click here\u00a0to register for the virtual webcast, &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T22:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026\",\"datePublished\":\"2026-02-13T22:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/\"},\"wordCount\":372,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=\",\"datePublished\":\"2026-02-13T22:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - Market Newsdesk","og_description":"Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI\u2122 (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 \u2013 28, 2026. Click here\u00a0to register for the virtual webcast, &hellip; Continue reading \"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-13T22:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026","datePublished":"2026-02-13T22:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/"},"wordCount":372,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/","name":"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=","datePublished":"2026-02-13T22:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDgwNSM3NDI2MzY5IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937065"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937065\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}